Biocon Share Price Surges After FDA Nod: What It Means for 2025 Investors
The market of biotech often makes headlines to become a nightmare for its investors; meanwhile, Bicon has got the headline with its remarkable achievement. On September 18, 2025, Biocon shares rose nearly 3%, closing at ₹368.40, after its subsidiary Biocon Biologics received U.S. FDA approval for two denosumab biosimilars, Bosaya™ and Aukelso™, which are used […]